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Abstract
Background: Neuromuscular electrical stimulation (NMES) has been investigated as a preventative measure for
intensive care unit-acquired weakness. Trial results remain contradictory and therefore inconclusive. As it has been
shown that NMES does not necessarily lead to a contractile response, our aim was to characterise the response of
critically ill patients to NMES and investigate potential outcome benefits of an adequate contractile response.
Methods: This is a sub-analysis of a randomised controlled trial investigating early muscle activating measures
together with protocol-based physiotherapy in patients with a SOFA score ≥ 9 within the first 72 h after admission.
Included patients received protocol-based physiotherapy twice daily for 20 min and NMES once daily for 20 min,
bilaterally on eight muscle groups. Electrical current was increased up to 70 mA or until a contraction was detected
visually or on palpation. Muscle strength was measured by a blinded assessor at the first adequate awakening and
ICU discharge.
Results: One thousand eight hundred twenty-four neuromuscular electrical stimulations in 21 patients starting on
day 3.0 (2.0/6.0) after ICU admission were included in this sub-analysis. Contractile response decreased from 64.4%
on day 1 to 25.0% on day 7 with a significantly lower response rate in the lower extremities and proximal muscle
groups. The electrical current required to elicit a contraction did not change over time (day 1, 50.2 [31.3/58.8] mA;
day 7, 45.3 [38.0/57.5] mA). The electrical current necessary for a contractile response was higher in the lower
extremities. At the first awakening, patients presented with significant weakness (3.2 [2.5/3.8] MRC score). When
dividing the cohort into responders and non-responders (> 50% vs. ≤ 50% contractile response), we observed a
significantly higher SOFA score in non-responders. The electrical current necessary for a muscle contraction in
responders was significantly lower (38.0 [32.8/42.9] vs. 54.7 [51.3/56.0] mA, p < 0.001). Muscle strength showed higher
values in the upper extremities of responders at ICU discharge (4.4 [4.1/4.6] vs. 3.3 [2.8/3.8] MRC score, p = 0.036).
Conclusion: Patients show a differential contractile response to NMES, which appears to be dependent on the severity
of illness and also relevant for potential outcome benefits.
Trial registration: ISRCTN ISRCTN19392591, registered 17 February 2011
Keywords: Neuromuscular electrical stimulation, Intensive care unit-acquired weakness, Critical illness, Critical illness
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Introduction
Critical illness and intensive care treatment can lead to
severe impairments of physical function, cognitive cap-
abilities and mental health, which directly affect the indi-
viduals’ daily living, e.g. return to work [1–8]. The
physical impairments, in terms of muscular weakness
and reduced walking distance, directly affect short-term
outcome, as patients suffering from weakness are less
likely to be weaned from mechanical ventilation, dis-
charged from the hospital or survive [4]. These impair-
ments can persist at least up to 5 years after discharge
from the intensive care unit (ICU) [9]. Therapeutic options
that have been the focus of investigations throughout the
last decade are early mobilisation and neuromuscular elec-
trical stimulation (NMES). Both of these options have
yielded positive as well as negative results in recent random-
ized controlled trials [10–14]. NMES is able to elicit muscle
contractions in unconscious or sedated and therefore unco-
operative patients. As it is possible to initiate this form of
treatment in the early phase of critical illness, even if the pa-
tient has to remain heavily sedated, it was reasoned to be a
promising therapeutic option to target muscular patho-
physiological processes in their beginning stages [15, 16].
While some trials were able to corroborate this hypothesis,
others yielded negative results [13, 14, 17]. Fossat and col-
leagues found no improvement in muscle strength or mobil-
ity in 314 patients receiving NMES of the M. quadriceps
femoris in conjunction with in-bed-cycling [13]. An under-
recognised aspect throughout recent NMES trials is the fact
that not every electrical impulse necessarily elicits an appro-
priate muscle contraction, as Segers et al. showed [18]. Sep-
sis, use of vasopressors and lower limb edema were
independent predictors for a missing contractile response to
NMES [18]. It remains unclear whether neuromuscular elec-
trical stimulation per se has a beneficial effect on the patient
or if the beneficial effect is a causal effect of the evoked
muscle contraction, which would be in line with current
knowledge about muscle physiology. In this case, the lack of
contraction from the electrical stimulation would leave study
results prone to bias. Furthermore, it remains unclear
whether the electrical stimulus during NMES has harmful
effects when not properly translated into a muscle contrac-
tion. Our aim was, therefore, to characterise the response of
critically ill patients to NMES, determine predictors for an
adequate or inadequate therapeutic response and investigate
potential benefits or detriments of an adequate respectively
inadequate muscular response to NMES.
Methods
Study design
This is a prospectively planned sub-analysis of a rando-
mised controlled exploratory interventional trial
(ISRCTN19392591) performed in two ICUs at the Charité
– Universitätsmedizin Berlin, a tertiary referral centre.
Ethical approval was granted by the institutional review
board (Charité EA 2/041/10).
Patients
Mechanically ventilated patients ≥ 18 years of age were in-
cluded on the basis of a Sepsis-related Organ Failure
Assessment (SOFA) score ≥ 9 within the first 72 h after
ICU admission as well as written informed consent by a
legal proxy and excluded if any of the following applied:
prior hospital treatment for longer than 7 days, illness pro-
hibiting early mobilisation, pre-existing neuromuscular
disease, insulin-dependent diabetes mellitus, Body Mass
Index > 35 kg/m2, not ambulating before admission or
poor prognosis with a high likelihood of death within the
next hours. Only patients randomised to receive NMES
were considered in this sub-analysis (for detailed study en-
rolment criteria, see [19]). Study staff had no influence on
treatment decisions and patients were treated according
to published standard operating procedures [20]. In order
to investigate if an adequate response to the NMES had
an influence on outcome and to define predictors for an
adequate response, we separated the population into re-
sponders, defined as > 50% contractile response to NMES,
and non-responders, with ≤ 50% contractile response to
NMES during the first 7 days of the study intervention.
Intervention
NMES was applied daily, beginning on the day of enrol-
ment up to day 28, for 20 min per muscle group bilat-
erally on eight different muscle groups (M. tibialis
anterior, M. triceps surae, M. vastus lateralis, posterior
thigh, M. biceps brachii, M. triceps brachii, wrist exten-
sors, wrist flexors). We utilised two devices of whom
each could stimulate four muscle groups simultaneously.
We never stimulated counteracting muscle groups at the
same time. Electrical impulses of 350 μs duration were
applied at a frequency of 50 Hz. On-time was 6/10 s and
off-time was 10/15 s with a ramp of 1 s (MUSKELaktiv
2-Kanal, schwa-medico®, Germany/ Physiomed-Expert-
2-Kanal, Physiomed®, Germany). Electrical current was
increased until muscle contraction was visible or palp-
able and then maintained at this level for the remainder
of the session. In case pain threshold was reached in
awake patients, electrical current was reduced to the last
level below the pain threshold and stimulation was per-
formed at that level. If a current of 70 mA failed to
evoke a sufficient response, electrical current was not in-
creased further, and the stimulation level was set to 40
mA for the session (Additional file 1: Table S2a). Data
on contraction as well as electrical current were docu-
mented separately for every NMES session as well as
muscle stimulated. For our analysis, only electrical
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currents from stimulations that lead to a contractile re-
sponse were respected.
Outcome
Muscle strength was assessed via Medical Research
Council (MRC) score on the first day patients were suffi-
ciently awake as well as at discharge from the ICU. Only
patients with an MRC assessment at both timepoints
were included in MRC analysis. Mean MRC scores were
calculated for each patient. We excluded specific muscle
groups from mean MRC score calculation if valid muscle
strength assessment was not feasible due to clinical reasons
(e.g. external fixators or casts). The day patients were suffi-
ciently awake was determined by fulfilment of the following
criteria on two consecutive days: first, Richmond Agitation
and Sedation Score between − 1 and + 1, and second, an
adequate response to three or more out of the following
five verbal commands: “Open/close your eyes,” “Look at
me,” “Open your mouth and put out your tongue,” “Nod
your head” and “Raise your eyebrows when I have counted
up to 5.” Contractile response to the electrical muscle
stimulation was confirmed if a muscle contraction was
either visible or palpable, or in the case patients were suffi-
ciently awake, if a contraction was reported.
Non-excitable muscle membrane as an electrophysio-
logical predictor for Critical Illness Myopathy was diag-
nosed via a direct muscle stimulation compound muscle
action potential cut-off value of < 3.0 mV [21].
We included the first 7 days of the ICU stay into our
investigations as it has been shown that pathophysio-
logical processes already enormously influence the pa-
tient during that time and our intervention, specifically
NMES, is predestined for the early phase of the disease
trajectory as it can be properly applied in sedated, un-
conscious and uncooperative patients.
Statistical analysis
Values for categorical variables are shown as count and
percentage, while values for metric variables are shown
as median and interquartile range (IQR). Statistical dif-
ference for metric variables was tested with the Mann-
Whitney U test for independent samples and Wilcoxon
test for dependent samples. Chi-square test was used to
test for statistical difference for categorical variables. A
receiver operating characteristics (ROC) analysis was
performed to determine a SOFA score cut-off value that
predicts non-responders to NMES as well as a mA value
that is sufficient to stimulate all responders. Sensitivity,
specificity and area under the curve (AUC) are reported
for the receiver operating characteristics analysis. The
Pearson correlation coefficient (r2) was calculated to de-
termine correlations between variables. A priori, a p
value < 0.05 was defined to indicate statistical
significance.
Results
During the 2-year inclusion period, 468 out of 3147 patients
that were admitted to two ICUs within the Charité – Uni-
versitätsmedizin Berlin fulfilled the inclusion criteria. Fifty of
these patients were successfully enrolled in the trial and ran-
domised. Further information regarding the enrolment
process has been published before [19]. For this sub-analysis,
only patients receiving NMES (n = 21) were considered
(Table 1).
In the 21 patients treated with NMES, a total of 1824
muscle groups were stimulated during the first 7 days of
treatment. These stimulations were equally distributed
between upper (n = 886) and lower (n = 938) extremities
(p = 0.522). On day 1 of NMES, only 64.4% of stimula-
tions led to a contractile response with a significant dif-
ference between upper (100%) and lower (41.7%)
extremities (p = 0.001). This difference could consistently
Table 1 Baseline characteristics
n 21
Sex (m/f) 16/76.2% / 5/
23.8%
Age (years) 53.0 (45.0/70.0)
Weight (kg) 85.0 (75.0/100.0)
Height (m) 1.78 (1.74/1.80)
BMI (kg/m2) 27.1 (24.2/30.9)









SOFA at ICU admission 13.0 (11.0/15.0)
APACHE II at ICU admission 25.0 (20.0/28.0)
SAPS2 at ICU admission 58.0 (47.0/65.0)
GCS at ICU admission 5.0 (3.0/6.0)
Time until first awakening (days) 17.0 (10.0/25.0)
ICU length of stay (days) 32.0 (21.0/43.0)
Percent of days with RASS > − 3 during ICU stay 64.3 (37.5/79.3)
Noradrenalin (μg/kg min) 0.07 (0.05/0.11)
Time requiring noradrenalin (days) 12.0 (9.0/18.0)





Start of NMES treatment after ICU admission (days) 3.0 (2.0/6.0)
Values for metric variables are presented as median and interquartile range
and for categorical variables as count and percentages. BMI = Body Mass
Index; SOFA = Sepsis-related Organ Failure Assessment; ICU = intensive care
unit; APACHE II = Acute Physiology and Chronic Health Evaluation II; SAPS 2
= Simplified Acute Physiology Score 2; GCS = Glasgow Coma Scale; RASS
= Richmond Aggitation Sedation Scale; NMES = Neurmuscular
electrical stimulation





Fig. 1 (See legend on next page.)
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be observed until day 7 (Fig. 1a + b). Nevertheless, a sig-
nificant correlation for contractile response between
upper and lower extremities was observed (k = 0.687,
r2 = 0.472, p = 0.001). Contractile response declined
throughout the 7-day observation period from 64.4 to
25.0% overall. We similarly observed a decrease in con-
tractile response for upper (100.0 to 58.3%) and lower
(41.7 to 12.5%) extremities (Fig. 1a + b) (Additional file
1: Table S2b).
Furthermore, the results showed that the proximal
muscle groups overall are less likely to respond to
NMES than the distal muscle groups (median [IQR]
proximal 40.7 [22.5/60.4] vs. distal 75.0 [38.0/91.7] %,
p < 0.001). This finding is evident in both upper (median
[IQR] proximal 73.2 [42.1/88.7] vs. distal 79.1 [72.5/94.6]
%, p = 0.047) as well as the lower extremities (median
[IQR] proximal 8.3 [0.0/45.8] vs. distal 52.5 [3.6/87.9] %,
p = 0.003). The M. vastus lateralis was the least likely to
respond to neuromuscular electrical stimulation (Fig. 1c)
(Additional file 1: Table S2b).
The threshold of electrical current that led to a con-
tractile response did not significantly change between
day 1 and 7 for all muscle groups taken together (me-
dian [IQR] day 1, 50.2 [31.3/58.8] mA; day 7, 45.3 [38.0/
57.5] mA) as well as for upper (median [IQR] day 1, 47.9
[24.4/60.5] mA; day 7, 44.4 [32.1/57.9] mA) and lower
extremities (median [IQR] day 1, 49.3 [41.8/57.3] mA;
day 7, 45.9 [37.1/49.8] mA) separately (Fig. 1d + e).
Nevertheless, there was a significant difference between
the upper and lower extremities observable on days 2, 3,
4, 5 and 6 with a higher electrical current mostly neces-
sary in the lower extremities. The applied electrical
current between upper and lower extremities correlated
significantly (k = 0.710, r2 = 0.505, p = 0.002) (Additional
file 1: Table S2b).
At first adequate awakening, all patients presented
with significant weakness overall (median [IQR] 3.2 [2.5/
3.8] MRC score) as well as for upper (median [IQR] 3.1
[2.4/3.8] MRC score) and lower extremities (median
[IQR] 3.0 [2.9/3.8] MRC score) individually (Fig. 1c, f, g).
Until discharge, an increase was observable overall (me-
dian [IQR] 3.5 [3.0/3.9] MRC score), for upper (median
[IQR] 3.8 [2.9/4.0] MRC score) and for lower extremities
(median [IQR] 3.8 [3.1/4.0] MRC score), while statistical
significance was only reached for the lower extremities
(p = 0.042) (Fig. 1f, g). Muscle strength between upper
and lower extremities at first awakening as well as at dis-
charge showed a significant correlation (first awakening
k = 0.864, r2 = 0.746, p < 0.001; ICU discharge k = 0.751,
r2 = 0.564, p < 0.001).
Using the contractile response cut-off value, 8 patients
were classified as responders (> 50% contractile response
during the first 7 days) and 13 were classified as non-re-
sponders (≤ 50% contractile response during the first 7
days). Univariate analysis revealed a significantly higher
SOFA score in non-responders at admission to the ICU.
Baseline characteristics were otherwise balanced includ-
ing norepinephrine treatment (Table 2).
When comparing the contractile response from re-
sponders to non-responders, we see a significantly
greater proportion of stimulations leading to an ad-
equate contractile response in responders (responders
vs. non-responders median [IQR] both, 83.7 [73.4/93.5]
vs. 35.0 [20.2/44.2] %, p < 0.001; upper extremities, 91.1
[86.6/99.1] vs. 67.0 [40.9/74.1] %, p < 0.001; lower ex-
tremities, 77.7 [62.5/90.2] vs. 7.1 [1.8/23.2] %, p = 0.002),
indicating that our cut-off value was sufficient in distin-
guishing between patients that respond well to those
who do not (Fig. 2a–d). Interestingly, no decrease in
contractile response over time was observed in re-
sponders as opposed to non-responders (Additional file 2:
Figure S1). When evaluating contractile response for all
muscle groups separately, we also observed a consistent,
remarkable and significant difference between re-
sponders and non-responders. Furthermore, it became
evident that except for the dorsal thigh and M. vastus
lateralis, the difference in response between upper and
lower extremities is only significant for non-re-
sponders (Fig. 2d). This difference in contractile re-
sponse is also reflected by the electrical current that was
necessary to elicit a contraction if possible at all, as it
was significantly higher in non-responders overall (re-
sponders vs. non-responders median [IQR] 38.0 [32.8/
42.9] vs. 54.7 [51.3/56.0] mA, p < 0.001) and for upper
extremities (responders vs. non-responders median
[IQR] 32.6 [30.6/37.3] vs. 54.7 [45.4/56.0] mA, p <
0.001). Interestingly, no difference in electrical current
was observed for lower extremities (responders vs. non-
(See figure on previous page.)
Fig. 1 Relative contractile response, electrical current and muscle strength during NMES. a Relative contractile response decreases between day 1
and day 7 without reaching statistical significance. b Upper extremities show a significantly higher response rate to NMES on days 1, 2, 3, 4, 5
and 7 in comparison to lower extremities. c Muscle strength and contractile response for all muscle groups separately. M. vastus lateralis shows
the lowest response to NMES. d Electrical current required to elicit a muscle contraction remains unchanged between day 1 and day 7. e A
significant difference in electrical current required to elicit a muscle contraction can be observed on days 2, 3, 4, 5 and 6 when comparing upper
and lower extremities. f Muscle strength increase for both extremities between first awakening and ICU discharge does not reach statistical
significance. g The increase in muscle strength between first awakening and ICU discharge reaches statistical significance for lower extremities. All
values are shown as median and interquartile range. Statistical significance was calculated via Mann-Whitney U test or Wilcoxon signed-rank test
as appropriate. A p < 0.05 is indicated by "+" in b and e. ICU = intensive care unit; MRC = Medical research council
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responders median [IQR] 44.6 [31.1/46.1] vs. 54.4 [33.0/
58.3] mA, p = 0.140) (Fig. 2e–g) (Additional file 3: Table
S1). Muscle strength at first awakening showed no statis-
tically significant differences between responders and
non-responders in the upper extremities (responders vs.
non-responders median [IQR] 3.8 [3.4/4.2] vs. 3.0 [2.0/
3.4] MRC score, p = 0.145), lower extremities (re-
sponders vs. non-responders median [IQR] 3.7 [3.3/3.7]
vs. 2.9 [2.4/3.9] MRC score, p = 0.630) and overall (re-
sponders vs. non-responders median [IQR] 3.8 [3.4/4.0]
vs. 3.1 [2.1/3.5] MRC score, p = 0.282) (Figs. 2h–j and 3 a).
At ICU discharge, a statistically significant difference in
muscle strength can be observed with higher muscle
strength in the upper extremities of responders (re-
sponders vs. non-responders median [IQR] 4.4 [4.1/4.6]
vs. 3.3 [2.8/3.8] MRC score, p = 0.036), while in lower
extremities (responders vs. non-responders median [IQR]
4.3 [3.5/4.6] vs. 3.6 [3.1/4.0] MRC score, p = 0.376) and
overall (responders vs. non-responders median [IQR] 4.3
[3.8/4.6] vs. 3.5 [2.8/3.9] MRC score, p = 0.145) statistical
significance was not reached (Fig. 2h–j and 3b).
The proportion of contractile responses to NMES
correlated inversely with the applied electrical
current overall (k = − 0.746, r2 = 0.556, p < 0.001) as
well as for upper extremities (k = − 0.653, r2 = 0.427,
p = 0.002). No correlation between electrical current
and contractile response was found for the lower
extremities.
The receiver operating characteristics analysis (AUC
0.962; p = 0.001) revealed that an electrical current of
50.1 mA elicits a contraction in responders with a sensi-
tivity of 100.0% and a specificity of 84.6%.
Contractile response furthermore correlates inversely
with the SOFA score at admission (k = − 0.544, r2 =
0.296, p = 0.011). A SOFA score ≤ 13.5 has a sensitivity
of 75% and a specificity of 61.5% to identify responders
(AUC 0.788; p = 0.03) (Fig. 4a, b).
Contractile response to NMES presented no statisti-
cally significant difference in patients with electrophysio-
logically diagnosed non-excitable muscle membrane in
comparison to patients with an excitable muscle mem-
brane (non-excitable muscle membrane vs. excitable
Table 2 Univariate analysis
Responder Non-responder p value
Patients/stimulations (n) 8/702 13/1122
Sex (m/f) 7/87.5% / 1/12.5% 9/69.2% / 4/30.8% 0.340
Age (years) 56.0 [36.5/71.0] 53.0 [47.0/70.0] 0.645
Weight (kg) 80.0 [70.0/92.5] 92.0 [75.0/109.0] 0.301
Height (m) 1.80 [1.77/1.83] 1.76 [1.70/1.80] 0.500
BMI (kg/m2) 26.5 [22.6/29.0] 27.8 [25.5/33.6] 0.210
Diagnosis responsible for ICU admission ARDS 2/25.0% 6/46.2% 0.118
Sepsis 0/0.0% 3/23.1%
Multiple trauma 4/50.0% 3/23.1%
Neurologic 2/25.0% 0/0.0%
Miscellaneous 0/0.0% 1/7.7%
SOFA at ICU admission 12.0 [9.5/13.5] 14 [12.0/16.0] 0.030
APACHE II at ICU admission 24.0 [17.0/27.0] 25.0 [23.0/29.0] 0.414
SAPS2 at ICU admission 43.0 [33.0/61.5] 61.0 [57.0/66.0] 0.089
GCS at ICU admission 5.5 [3.0/7.5] 3.0 [3.0/6.0] 0.456
Time until first awakening (days) 12.0 [7.5/15.5] 20.5 [10.0/42.0] 0.287
ICU length of stay (days) 28.0 [19.0/36.0] 39.0 [25.0/49.0] 0.185
Percent of days with RASS > − 3 during ICU stay 50.2 [26.9/94.6] 71.4 [50.0/79.2] 0.750
Noradrenalin (μg/kg min) 0.08 [0.03/0.10] 0.07 [0.06/0.11] 0.414
Time requiring noradrenalin (days) 12.0 [3.5/15.5] 12.0 [11.0/25.0] 0.595
Survivors/non-survivors 7/87.5% / 1/12.5% 11/84.6% / 2/15.4% 0.854
Non-excitable muscle membrane/excitable muscle membrane 2/33.3% / 4/66.7% 5/62.5% / 3/37.5% 0.280
Start of NMES treatment after ICU admission (days) 3.0 (2.0/6.0) 4.0 (2.0/6.0) 0.750
Values for metric variables are presented as median and interquartile range and for categorical variables as count and percentages. Mann-Whitney U or chi-square
test were used to calculate statistical significance. The statistically significant p-value (p < 0.05) is italicised to highlight it. BMI = Body Mass Index; SOFA = Sepsis-
related Organ Failure Assessment; ICU = intensive care unit; APACHE II = Acute Physiology and Chronic Health Evaluation II; SAPS 2 = Simplified Acute Physiology
Score 2; GCS = Glasgow Coma Scale; RASS = Richmond Aggitation Sedation Scale; NMES = Neurmuscular electrical stimulation





Fig. 2 Relative contractile response, electrical current and muscle strength in comparison between responders and non-responders. Relative
contractile response is significantly higher in responders as opposed to non-responders during the first 7 days after ICU admission a for both
extremities, b for upper extremities, c for lower extremities and d for all muscle groups separately. Electrical current required to elicit a contractile
response is significantly higher in non-responders as opposed to responders during the first 7 days after ICU admission e for both extremities and
f for upper extremities, while no difference can be observed for g lower extremities. Muscle strength measured via MRC scored at ICU discharge
shows significantly higher values in responders as opposed non-responders for i upper extremities, while not reaching statistical difference for h
both extremities as well as j lower extremities at first adequate awakening as well as ICU discharge and h upper extremities at first adequate
awakening. All values are shown as median and interquartile range. Statistical significance was calculated via Mann-Whitney U test or Wilcoxon
signed-rank test as appropriate. MRC = Medical research council
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muscle membrane median [IQR] 44.2 [36.1/53.3] vs.
78.0 [42.5/88.7] %, p < 0.128).
Discussion
This retrospective sub-analysis aimed to outline the
characteristics of, as well as predictors for, a contractile
response to NMES, and also potential clinical benefits
resulting from an adequate response to NMES. We were
able to show that at the initiation of NMES, only two
thirds of stimulations led to a contractile response in
our cohort and that this number declined to one third
throughout the first 7 days of stimulation, which we
think is due to progressing pathophysiological processes.
Established mechanisms that would hypothetically
contribute to this effect are channelopathy, decreasing
metabolic flexibility, advanced muscle atrophy and
edema. Interestingly, the upper extremities proved to re-
spond to NMES more frequently than the lower extrem-
ities and the distal extremities more frequently than the
proximal extremities. If contractile response was present,
the required electrical current for a muscle contraction
did not change within the first 7 days, while in the lower
extremities higher currents were usually required to
elicit a contractile response. Patients classified as re-
sponders to NMES were shown to have a lower SOFA
score, to require a lower electrical current and to have a
significantly improved upper extremity muscle strength at
discharge. An electrical current of 50.1mA was sufficient
a
b
Fig. 3 Muscle strength at first adequate awakening and ICU discharge for all muscle groups separately. Muscle strength difference measured via
MRC score at a first awakening and b ICU discharge in responders and non-responders. MRC = Medical research council
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to adequately stimulate responders to NMES, which can
be identified by a SOFA score ≤ 13.5.
NMES has been investigated in the context of critical
illness and ICU-acquired Weakness for almost a decade
without a clear conclusion regarding its effectiveness
mainly due to controversial and incoherent study results
[13, 14, 17]. As an example, an improvement in muscle
strength using NMES was shown by Karatzanos and col-
leagues [22]. On the other hand, Kho et al. were not able
to reproduce these findings [23]. An aspect that is crit-
ical when reporting interventional trials is whether the
intervention was delivered as planned. Segers et al. first
suggested that not every electrical impulse during NMES
is converted into a muscle contraction [18]. Neverthe-
less, most trials on NMES published to date merely re-
port the number or total duration of NMES sessions
without mentioning the relative amount of stimulations
successfully translated into a muscular contraction, a po-
tentially useful surrogate indicating successful delivery of
NMES. A lack of contractile response in the participants
could be one cause for the incoherent and contradictory
study results in NMES interventional trials throughout
the past years. Contractile response was only reported in
one outcome-focused interventional trial by Rodriguez
and colleagues, who conducted an intraindividual com-
parison in 16 patients [17]. The muscular response rate
of 77% was relatively high compared to our observations as
well as to the numbers presented by Segers et al. [17, 18].
Interestingly, they also report an increase in muscle
strength at ICU discharge, which is similar to the increased
muscle strength we found in the upper extremities of our
responder group at ICU discharge [17]. When looking at
markers for muscle mass—extremity circumference or
muscle thickness via ultrasound—Rodriguez et al. found no
effect due to NMES. Interestingly, the dissociation between
muscle mass and function has been repeatedly observed in
critically ill patients shortly after ICU admission as well as
6months after ICU discharge [24, 25]. Nevertheless could
muscle strength only be assessed via a nonvolitional
method based on electrical stimulation of a muscle contrac-
tion in the trial investigating the timeframe shortly after
ICU admission. The effect of an impaired contractile re-
sponse has on this form of muscle strength measure-
ment in critically ill patients is unknown [24]. An
impaired bioenergetic status has been shown to be of
relevance for the development of muscle weakness
during the ICU stay and could be a plausible culprit
for the difference between muscle mass and muscle
function [26]. Future trials are required to elucidate
the exact mechanisms.
Our investigation into multiple muscle groups revealed
that the M. vastus lateralis has the lowest response rate to
NMES and that there is a significant difference between
upper and lower extremities in the response to NMES.
Based on these facts, we think another factor introducing
significant bias into most investigations of NMES is the
fact that almost all of them only investigated the lower ex-
tremities or solely the quadriceps femoris, which, accord-
ing to our findings, would carry a high risk of yielding
negative study results due to lack of contractile response
[13, 14, 23, 27, 28]. A standardised NMES reporting sheet
(Additional file 4: Standardised NMES Reporting Sheet)
was developed by us in order to improve reporting of
NMES protocols and responder rates in future trials and
through that enable an adequate comparison of patient
cohorts, protocols and muscle groups.
We have shown that a maximum electrical current of
50 mA is sufficient to stimulate all patients that respond
adequately to NMES. This number was doubled and al-
most tripled in some studies, and while we did not ob-
serve any harm from NMES with electrical currents up
to 70 mA in our cohort, further investigations are
needed to rule out any harm from electrical currents
above our defined threshold [29].
a b
Fig. 4 Correlation and ROC curve for contractile response and SOFA. Relative contractile response between days 1 and 7 correlates with a SOFA
score. b ROC curve for SOFA score in patients with adequate contractile response to neuromuscular electrical stimulation. SOFA = Sepsis-related
Organ Failure Assessment; ROC = receiver operating characteristics
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ICU-acquired weakness has been shown to develop
early during critical illness, while the likelihood of
developing it increases with the severity of critical illness
[15, 16, 30]. In agreement with our results, Segers and
colleagues have found that patients with higher disease
severity, in their case differentiated by sepsis or no sep-
sis, are less likely to respond to NMES [18]. Further-
more, we were able to show that distal muscle groups
respond better to NMES than proximal muscle groups,
which is in accordance with DeJonghe et al., who
showed that proximal muscle groups are more severely
affected by ICU-acquired weakness than distal muscle
groups [31]. Due to the overlap between characteristics
of, and risk factors for, ICU-acquired weakness and in-
sufficient response to NMES, it appears likely and plaus-
ible that pathophysiological mechanisms involved in the
development of ICU-acquired weakness are also respon-
sible for hampering contractile response to NMES [30].
Furthermore, could differences in impedance due to
edema or fat mass, a different electrode to muscle ratio
or differing adaptive reactions to therapy have an im-
portant impact on contractile response [18]. Segers et al.
were not able to find an association between electro-
physiological characteristics of critical illness myopathy
and the lack of contractile response, within our data
such an association could not be shown as well but as
our analysis is of exploratory nature a large sample size
in future trials might yield different results [18]. As such,
future investigations specifically dedicated to this ques-
tion are necessary, in order to further elucidate the con-
nection between electrophysiologic abnormalities and
lack of contractile response.
ICU-acquired weakness is a clinical syndrome defined
by an average MRC score < 4 [32]. Multiple pathophysio-
logical mechanisms, e.g. muscle wasting, bioenergetic fail-
ure and membrane inexcitability, have been described in
the context of ICU-acquired weakness [15, 16, 21, 33]. We
therefore hypothesise that depending on the aetiology,
different pathophysiological mechanisms could be pre-
dominantly responsible for the development of ICU-
acquired weakness and also be the reason patients
respond differently to interventions such as NMES.
Future studies should further evaluate these underlying
mechanisms in the development of ICU-acquired weak-
ness in order to more closely define different types of
ICU-acquired weakness and possibly identify sub-cohorts
that respond to and consequently benefit from the differ-
ent interventions.
Our pilot analysis is limited by the number of patients
as multivariate analysis to investigate independency of
association between, for example, SOFA score and re-
sponder status could not be performed. Furthermore, as
our ICU admissions were not planned, we were not able
to obtain pre-admission muscle strength values. Our
muscle strength values at first awakening will therefore
already be affected by the intervention, and correction
for potential baseline differences is not possible. We did
not included patient with pre-existing neuromuscular
disease in order to keep bias due to missing pre-admis-
sion values to a minimum. Since our protocol did not
include an electrical current above 70mA, we are not
able to reach any conclusion—neither beneficial nor
harmful effects—regarding NMES with higher electrical
currents. We see that 50.1 mA is a good cut-off to differ-
entiate responders and non-responders on this basis we
do not believe increasing electrical current further will
increase responder rates.
Conclusion
Different muscle groups as well as different patients
show a varying response to NMES, which appears to be
dependent on multiple factors that are linked to the re-
spective pathomechanisms behind the development of
the ICU-acquired weakness. Since we observed a varying
degree of clinical improvement when comparing patients
that responded adequately to NMES to those who did
not, it is strongly suggested that response rates to NMES
should be reported in future trials (Additional file 4:
Standardised NMES Reporting Sheet) and evaluated in
relation to clinical outcomes. The described difference in
response rates to NMES may explain the controversial
findings of previous trials and improve the quality of evi-
dence in future critical care NMES trials.
Additional files
Additional file 1: Table S2. a Neuromuscular electrical stimulation
reporting: protocol specifications. Specifications of the developed NMES
protocol. b Neuromuscular electrical stimulation reporting: stimulation
and contraction specifications. Specification of the applied NMES.
Electrical current shows the median electrical current applied to patients
with a positive contractile response per muscle group and day.
Contractile response shows the percentage of patients with a positive
contractile response per muscle group and day. (XLSX 19 kb)
Additional file 2: Figure S1. Contractile response dynamics between
day 1 and day 7 in responders and non-responders. (PDF 30 kb)
Additional file 3: Table S1. Electrical current. Electrical current
necessary to elicit a contractile response for all muscle groups separately
for all patients as well as responders and non-responders. (PDF 266 kb)
Additional file 4: Standardised NMES Reporting Sheet. Standardised
NMES reporting sheet for NMES protocol and stimulation specifications.
(XLSX 17 kb)
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